PUBLIC COMPANY
save$BCRXBIOCRYST PHARMACEUTICALS INC
$BCRX8.1700+0.62%Durham, NC, USupdated 1d ago
community read0 votes
pipeline
6
marketed
2
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
1Phase 11Phase 21Phase 32Marketed1Unknown
Marketed
berotralstat hydrochloride
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…
Marketedperamivir
Influenzavirus A Infections
Phase 3navenibart
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…
Phase 2BCX-17725
Netherton Syndrome (Bamboo Hair)
Phase 1STAR-0310
Atopic Dermatitis (Atopic Eczema)
drugORLADEYO
1 INDICATIONS AND USAGE ORLADEYO ® is indicated for proph…
Plasma kallikrein
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study of Avoralstat In Participants With Diabetic Macular Edema
- phase3Berotralstat Treatment in Children With Hereditary Angioedema
- phase3Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
- phase312-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
- phase2Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
- phase2A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- phase2BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy
- phase1Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
🐶 Hiring Signal
next earnings Nov 2, 2026
News
- ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryBioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.fiercebiotech · 1mo ago
- BioCryst ends internal discovery programs, will close Alabama research facilityBioCryst Pharmaceuticals is winding down its own drug discovery work, saying that it plans to look for future drug programs externally. The company announced a plan to discontinue its internal disc…endpoints · 3mo ago
- Chiesi to buy KalVista in $1.9B deal for rare disease drugThe acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.biopharma_dive · 5mo ago
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that